Welcome to our dedicated page for Dermata Therapeutics news (Ticker: DRMA), a resource for investors and traders seeking the latest updates and insights on Dermata Therapeutics stock.
Dermata Therapeutics, Inc. (symbol: DRMA) is a clinical-stage biotechnology company based in San Diego, California, focused on the development and commercialization of novel pharmaceutical products for the treatment of medical and aesthetic skin conditions. The company leverages its proprietary Spongilla technology platform to create unique, topical treatments with multifaceted mechanisms of action.
Dermata's lead product candidate, DMT310, is a once-weekly topical treatment derived from a naturally sourced freshwater sponge. Designed to treat inflammatory skin diseases such as acne, rosacea, and psoriasis, DMT310 has shown significant promise in clinical trials. The Phase 3 STAR-1 clinical trial for moderate-to-severe acne is set to start enrolling patients in the second half of 2023, with topline results expected in the first quarter of 2025.
The company's second product candidate, DMT410, employs the Spongilla technology for the needle-free intradermal delivery of botulinum toxin. This product is being developed for the treatment of hyperhidrosis and various aesthetic skin conditions. Recent advancements include the issuance of a Japanese patent for DMT410 and ongoing partnership discussions to further its development.
Financially, Dermata has demonstrated robust fiscal management, raising $6.8 million in gross proceeds from financings in the first half of 2023. As of June 2023, the company reported $8.4 million in cash and cash equivalents. This funding is projected to sustain operations into the second quarter of 2024.
Key milestones include FDA feedback on the Phase 3 clinical trial design for DMT310 and successful capital raises. Dermata continues to focus on advancing its clinical programs and exploring potential partnerships to bring its innovative treatments to market. For more detailed information, visit Dermata's official website.
Dermata Therapeutics, Inc. (NASDAQ:DRMA) has appointed Brittany Bradrick to its Board of Directors and Audit Committee. Bradrick has over 25 years of experience in finance and corporate development in the life sciences sector. She has previously held senior roles at Neurelis and ViaCyte, and her expertise is expected to benefit Dermata's development of its product candidates, DMT310 and DMT410. This appointment follows Dr. Steven Mento's transition to a different committee role while remaining a director. Dermata focuses on treatments for medical and aesthetic skin conditions.
Dermata Therapeutics (NASDAQ:DRMA), a clinical-stage biotechnology company, announced that Gerry Proehl, its Chairman, President, and CEO, will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 a.m. ET. Dermata focuses on treating skin conditions with its lead product candidate, DMT310, aimed at acne, psoriasis, and rosacea. The company’s second candidate, DMT410, is designed for topical administration of botulinum toxin. A replay will be accessible on Dermata's website for 90 days.
Dermata Therapeutics announced positive efficacy and safety results from its Phase 1b proof of concept study evaluating DMT410, a topical treatment for aesthetic skin conditions. Key findings include observed improvements in pore size, luminosity, and overall skin brightness, lasting approximately 3 months. The study, involving 10 female patients, showed no adverse effects or distant spread of toxin. The company believes DMT410's delivery method expands market opportunities for botulinum toxins. Results were presented at The American Society for Dermatologic Surgery Annual Meeting.
Dermata Therapeutics (Nasdaq:DRMA) has enrolled its first patient in a Phase 2 trial for DMT310, aimed at treating moderate-to-severe rosacea, which affects approximately 16 million patients in the U.S. This trial, designed to evaluate the product's tolerability and efficacy over 12 weeks, anticipates topline results in the second half of 2022. DMT310 employs innovative Spongilla technology, targeting inflammatory pathways by inhibiting IL-17 production. If successful, it could redefine treatment options in dermatology, potentially becoming the first once-weekly topical solution for rosacea.
Dermata Therapeutics reported positive topline results from its DMT310 clinical trial for mild-to-moderate psoriasis, with 29.6% of patients achieving a PGA score of 0 or 1. The company successfully closed an upsized initial public offering (IPO) raising $18.0 million and appointed notable leaders to its Board and executive team. Dermata plans to present topline results from the DMT410 study on November 19, 2021, and initiate a Phase 2 study for DMT310 in rosacea in Q4 2021. As of September 30, 2021, Dermata had $12.6 million in cash, bolstered by its recent IPO.
Dermata Therapeutics (Nasdaq:DRMA) announced the presentation of efficacy and safety results for its Phase 1b proof of concept study evaluating DMT410 for treating multiple aesthetic skin conditions. The study, involving 10 patients, observed effects over 16 weeks and assessed various endpoints, including fine lines and luminosity improvements. Results will be presented by Dr. Rawaa Almukhtar at the ASDS Annual Meeting on November 19, 2021. DMT410 utilizes unique Spongilla technology for intradermal delivery of botulinum toxin.
Dermata Therapeutics (NASDAQ:DRMA) will host a virtual investor event on November 19, 2021, at 4:30 PM ET to present results of its DMT410 Phase 1b study targeting multiple aesthetic skin conditions. The event features presentations from Dr. Christopher Nardo and Gerry Proehl, focusing on the proof of concept evaluation initially shared at the American Society for Dermatologic Surgery meeting. DMT410 utilizes Dermata's Spongilla technology to deliver botulinum toxin topically and may offer a new treatment avenue for skin conditions.
Dermata Therapeutics (NASDAQ:DRMA) announced positive results from its Phase 1b trial of DMT310 for treating mild-to-moderate psoriasis. The study showed that 29.6% of patients achieved a Physician's Global Assessment (PGA) score of 0 or 1, while 25.9% had a Psoriasis Area Severity Index (PASI) score of 0 or 1 after 8 weeks. Additionally, there was a 19.6% reduction in pruritus. The treatment was reported to be safe with few adverse events. Dermata plans to advance DMT310 in further clinical investigations.
Dermata Therapeutics (Nasdaq:DRMA) announced an oversubscribed $18 million IPO, enhancing its clinical development focus. The company aims to release topline data from its DMT310 Phase 1b study for psoriasis in 4Q 2021 and initiate a Phase 2 study for rosacea later this year. Financial results reveal cash reserves of $427,202 as of June 30, 2021, down from $530,400 at year-end 2020. R&D expenses rose significantly to $867,197 for Q2 2021 from $411,949 in Q2 2020, reflecting increased clinical trial costs. General expenses also increased sharply, highlighting rising operational costs.
Dermata Therapeutics (NASDAQ:DRMA)(NASDAQ:DRMAW) will present efficacy and safety data from a Phase 1b study evaluating DMT410 as a new topical delivery mechanism for botulinum toxin aimed at aesthetic skin conditions at the ASDS 2021 Annual Meeting on November 19-21, 2021. The study involved 10 patients receiving DMT410, comprising a topical application of Spongilla powder followed by botulinum toxin, with observed outcomes over 16 weeks. The presentation signifies Dermata's commitment to innovative treatments in dermatology.
FAQ
What is the current stock price of Dermata Therapeutics (DRMA)?
What is the market cap of Dermata Therapeutics (DRMA)?
What does Dermata Therapeutics, Inc. specialize in?
What is DMT310?
What is DMT410?
How much funding did Dermata raise in the first half of 2023?
When is the Phase 3 STAR-1 clinical trial for DMT310 expected to start?
What recent feedback did Dermata receive from the FDA?
What are the anticipated results from the STAR-1 clinical trial?
What is the financial outlook for Dermata?
Where is Dermata Therapeutics headquartered?
How can I find more information about Dermata Therapeutics?
